OCULAR THERAPEUTIX, INC: research and development expense
Research and development expense for OCULAR THERAPEUTIX, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All OCULAR THERAPEUTIX, INC financial histories
What this measure means
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
Exact concept: us-gaap:ResearchAndDevelopmentExpense. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2012-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 197,096,000 | USD | 2026-02-05 | 10-K · 0001104659-26-010664 |
| 2024-01-01 | 2024-12-31 | 127,635,000 | USD | 2026-02-05 | 10-K · 0001104659-26-010664 |
| 2023-01-01 | 2023-12-31 | 61,055,000 | USD | 2026-02-05 | 10-K · 0001104659-26-010664 |
| 2022-01-01 | 2022-12-31 | 53,462,000 | USD | 2025-03-03 | 10-K · 0001558370-25-002000 |
| 2021-01-01 | 2021-12-31 | 50,083,000 | USD | 2024-03-11 | 10-K · 0001558370-24-002902 |
| 2020-01-01 | 2020-12-31 | 28,694,000 | USD | 2023-03-06 | 10-K · 0001558370-23-002908 |
| 2019-01-01 | 2019-12-31 | 41,091,000 | USD | 2022-02-28 | 10-K · 0001558370-22-002363 |
| 2018-01-01 | 2018-12-31 | 36,915,000 | USD | 2020-03-12 | 10-K · 0001558370-20-002537 |
| 2017-01-01 | 2017-12-31 | 30,880,000 | USD | 2020-03-12 | 10-K · 0001558370-20-002537 |
| 2016-01-01 | 2016-12-31 | 27,065,000 | USD | 2019-03-07 | 10-K · 0001558370-19-001659 |
| 2015-01-01 | 2015-12-31 | 26,611,000 | USD | 2018-03-08 | 10-K · 0001558370-18-001678 |
| 2014-01-01 | 2014-12-31 | 18,880,000 | USD | 2017-03-10 | 10-K · 0001558370-17-001627 |
| 2013-01-01 | 2013-12-31 | 10,517,000 | USD | 2016-03-10 | 10-K · 0001193125-16-499184 |
| 2012-01-01 | 2012-12-31 | 11,540,000 | USD | 2015-03-20 | 10-K · 0001193125-15-099288 |
Related financial histories
- OCULAR THERAPEUTIX, INC: total assets
- OCULAR THERAPEUTIX, INC: total liabilities
- OCULAR THERAPEUTIX, INC: stockholders equity
- OCULAR THERAPEUTIX, INC: cash and cash equivalents
- OCULAR THERAPEUTIX, INC: net income or loss
- OCULAR THERAPEUTIX, INC: operating cash flow
- OCULAR THERAPEUTIX, INC: capital expenditure payments
- OCULAR THERAPEUTIX, INC: revenue
- OCULAR THERAPEUTIX, INC: contract revenue excluding tax
- OCULAR THERAPEUTIX, INC: financing cash flow
- OCULAR THERAPEUTIX, INC: investing cash flow
- OCULAR THERAPEUTIX, INC: retained earnings or deficit
- OCULAR THERAPEUTIX, INC: basic weighted-average shares
- OCULAR THERAPEUTIX, INC: diluted weighted-average shares
- OCULAR THERAPEUTIX, INC: basic earnings per share
- OCULAR THERAPEUTIX, INC: diluted earnings per share
- OCULAR THERAPEUTIX, INC: net property, plant and equipment
- OCULAR THERAPEUTIX, INC: share-based compensation expense
- OCULAR THERAPEUTIX, INC: operating income or loss
- OCULAR THERAPEUTIX, INC: current assets
- OCULAR THERAPEUTIX, INC: interest expense
- OCULAR THERAPEUTIX, INC: current liabilities
- OCULAR THERAPEUTIX, INC: current accounts payable
- OCULAR THERAPEUTIX, INC: net current accounts receivable
- OCULAR THERAPEUTIX, INC: operating expenses
- OCULAR THERAPEUTIX, INC: net inventory
Inspect the source
- Entity
- OCULAR THERAPEUTIX, INC / CIK 0001393434
- Captured
- 2026-09-20T07:59:40.792Z
- SEC response SHA-256
49208a819b449e933d340040d01c62c3d6db52e27de000c4850c8c33e540bcb2
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001393434.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))